ClinicalTrials.gg
CompletedNCT00425373Updated Apr 29, 2011Results posted

Efficacy and Safety of Valsartan and Amlodipine in Patients With Essential Hypertension

A Phase 2/3 interventional study of Valsartan + amlodipine 40/2.5 mg and Valsartan + amlodipine 40/5 mg in Essential Hypertension, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2011-04-29.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,474
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing valsartan in Essential Hypertension — 2 open to participants now, 2 under way, 1 of them phase 3. Valsartan · Essential Hypertension.

Enrollment
Largest of 10
1,474 · median 392
Started
2006
the only one that year
Phase 2/3
Only one
of the 10
Registered
2nd of 10
by date
Lead sponsor
3 of 10
Novartis Pharmaceuticals

Among the 10 studies testing valsartan in Essential Hypertension, this one has the largest enrollment, is the only one that started in 2006, is the only one in phase 2/3, and was the 2nd registered.

Essential Hypertension

480 studies on the registry are indexed under Essential Hypertension; 76 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

2 of the 10 studies testing valsartan in Essential Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing valsartan in Essential Hypertension, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of fixed combination of valsartan (40 mg and 80 mg) and amlodipine (2.5 mg and 5 mg), valsartan and amlodipine alone, and placebo in reducing blood pressure. The study will investigate the dose response relationship for the combinations, monotherapies, and placebo.

03

Conditions studied

  • Essential Hypertension

Keywords

  • Hypertension, Valsartan, Amlodipine, high blood pressure
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with essential hypertension measured by electronic hemodynamometer. - - Patients must satisfy the following criteria.

    1. MSDBP \<110 mmHg and MSSBP \<180 mmHg at Visit 1
    2. MSDBP ≥ 90 mmHg and \< 110 mmHg and MSSBP \< 180 mmHg at Visit 2
    3. MSDBP ≥ 95 mmHg and \< 110 mmHg and MSSBP \< 180 mmHg at Visit 3
    4. The absolute difference in MSDBP between Visit 2 and 3 is ≤ 10 mmHg
  • Male or female outpatients.
  • Aged => 20 and =\< 80 years (at the time of signing ).
  • Patients who have written informed consent to participate in this study.

Exclusion criteria

Exclusion criteria

  • Pregnant women, nursing (lactating) mothers, women suspected of being pregnant, or women who wish to be pregnant during the study, women of .
  • Patients with secondary hypertension or suspected of having secondary hypertension.
  • Patients with a history of malignant hypertension.
  • Patients with an inability to completely discontinue all prior antihypertensive medications safely for a period of 12 weeks as required by the protocol.
  • Patients with or with a history of any of the following diseases or signs: Cardiac disease, renal disease, cerebrovascular disorder
  • Patients with a allergy (asthma on pharmacotherapy, multi-drug allergy, or drug-induced or food-induced anaphylactic reactions).
  • Patients hypersensitive to AII receptor antagonists, calcium channel blockers or dihydropyridine derivatives.
  • Known moderate or malignant retinopathy.
  • Patients with or with a history of pancreatitis. Patients with pancreatic injury, or evidence of impaired pancreatic function/injury within 12 months of Visit 1.
  • Patients with any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
  • Patients with volume depletion based on the investigator's or subinvestigator's clinical judgment using vital signs, skin turgor, moistness of mucous membrane and laboratory values.
  • Patients who are found to have low Na and K (Na \<130 mEq/L, K \<3.3mEq/L) or high in these parameters (Na ≥ 152 mEq/L, K ≥ 5.2 mEq/L) by laboratory tests at Visit 1.
  • Patients with type I diabetes mellitus on treatment with insulin, or patients with type II diabetes with poor glucose control defined as a glycosylated () > 8.0% at Visit 1.
  • Patients with or with a history of malignant tumors including leukemia and lymphoma, treated or untreated, within the past 5 years of Visit 1 whether or not there is evidence of local recurrence or (except for localized basal cell carcinoma of the skin).
  • Patients with any severe, life-threatening disease within the past 5 years. Patients with a history of diseases such as rheumatoid arthritis and systemic lupus erythematosus.
  • Any surgical or medical condition, which in the opinion of the investigator or subinvestigator, place the patient at higher risk from his/her participation in the study, or are likely to prevent the patient from complying with the requirement of the study or completing the trial period.
  • Patients who have with or with a history of drug or alcohol abuse within the last 2 years of Visit 1. Patients who have received other product within 12 weeks of Visit 1.
  • Any chronic inflammatory condition needing chronic anti-inflammatory drug therapy.
  • Persons directly involved in the execution of this study.
  • Patients who are considered unlikely to comply with the requirements specified in the protocol by the investigator or subinvestigator.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,474 participants (actual)

Study arms

  • Experimental
    Valsartan + amlodipine 40/2.5 mg

    Drug: Valsartan + amlodipine 40/2.5 mg

  • Experimental
    Valsartan + amlodipine 40/5 mg

    Drug: Valsartan + amlodipine 40/5 mg

  • Experimental
    Valsartan + amlodipine 80/2.5 mg

    Drug: Valsartan + amlodipine 80/2.5 mg

  • Experimental
    Valsartan + amlodipine 80/5 mg

    Drug: Valsartan + amlodipine 80/5 mg

  • Active comparator
    Valsartan 40 mg

    Drug: Valsartan 40 mg

  • Active comparator
    Valsartan 80 mg

    Drug: Valsartan 80 mg

  • Active comparator
    Amlodipine 2.5 mg

    Drug: Amlodipine 2.5 mg

  • Active comparator
    Amlodipine 5 mg

    Drug: Amlodipine 5 mg

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugValsartan + amlodipine 40/2.5 mg

    Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily

  • DrugValsartan + amlodipine 40/5 mg

    Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily

  • DrugValsartan + amlodipine 80/2.5 mg

    Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily

  • DrugValsartan + amlodipine 80/5 mg

    Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily

  • Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily

  • Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily

  • Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily

  • Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily

  • DrugPlacebo

    4 tablet and 2 capsule placebos taken once daily

06

What researchers measure

Primary outcomes

  1. Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)

    At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

    Time frame: Baseline to end of study (Week 8)

Secondary outcomes

  1. Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)

    At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

    Time frame: Baseline to end of study (Week 8)

  2. Percentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)

    At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

    Time frame: Baseline to end of study (Week 8)

  3. Percentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8)

    At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

    Time frame: Baseline to end of study (Week 8)

  4. Percentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8)

    At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

    Time frame: Baseline to end of study (Week 8)

07

Results

Posted Feb 4, 2011

Participant flow

Participant flow — Overall Study
MilestoneValsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/2.5 mgValsartan + Amlodipine 80/5 mgValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgAmlodipine 5 mgPlacebo
Started159167160162169163161161166
Completed154164157160159154154151148
Not completed533210971018
Withdrew: Adverse event220146238
Withdrew: Lost to follow-up010010000
Withdrew: Protocol violation101000053
Withdrew: Withdrawal by subject202140222
Withdrew: Lack of efficacy000013305

Outcome measures

PrimaryChange in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)

At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)
mm HgValsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/2.5 mgValsartan + Amlodipine 80/5 mgValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgAmlodipine 5 mgPlacebo
Change in Mean Sitting Diastolic Blood Pressure (MSDBP) From Baseline to End of Study (Week 8)-13.5 ± 0.62-16.5 ± 0.60-12.6 ± 0.62-17.0 ± 0.61-8.5 ± 0.60-8.8 ± 0.61-10.3 ± 0.61-13.4 ± 0.61-4.8 ± 0.61
SecondaryChange in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)

At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Least squares mean · mm Hg
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)
mm HgValsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/2.5 mgValsartan + Amlodipine 80/5 mgValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgAmlodipine 5 mgPlacebo
Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Study (Week 8)-16.7 ± 0.88-22.0 ± 0.86-16.9 ± 0.88-22.9 ± 0.87-9.3 ± 0.85-9.5 ± 0.87-13.6 ± 0.87-16.6 ± 0.87-4.4 ± 0.86
SecondaryPercentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)

At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)
Percentage of patientsValsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/2.5 mgValsartan + Amlodipine 80/5 mgValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgAmlodipine 5 mgPlacebo
Percentage of Patients Achieving MSDBP < 90 mmHg or a => 10 mm Hg Decrease Compared to Baseline at the End of the Study (Week 8)77.488.080.686.452.147.962.174.536.1
SecondaryPercentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8)

At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8)
Percentage of patientsValsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/2.5 mgValsartan + Amlodipine 80/5 mgValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgAmlodipine 5 mgPlacebo
Percentage of Patients Achieving MSDBP < 90mmHg at the End of the Study (Week 8)67.382.672.580.946.241.155.367.131.9
SecondaryPercentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8)

At study entry, blood pressure was measured in both arms using a standard method described in the protocol. The arm with the higher diastolic BP reading was used for the measurements at all subsequent visits. Blood pressure in the sitting position was measured after resting in a seated position for at least 5 minutes. The measurement was repeated a total of 3 times at intervals of 1 to 2 minutes. A negative number indicates lowered blood pressure.

Time frame:
Baseline to end of study (Week 8)
Reported as:
Number · Percentage of patients
Percentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8)
Percentage of patientsValsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/2.5 mgValsartan + Amlodipine 80/5 mgValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgAmlodipine 5 mgPlacebo
Percentage of Patients Achieving MSDBP < 90 mm Hg and MSSBP < 140 mm Hg at the End of the Study (Week 8)55.375.459.472.233.130.141.057.118.7

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/166 (1.2%)17/166 (10.2%)
Valsartan 40 mg—0/169 (0%)23/169 (13.6%)
Valsartan 80 mg—0/163 (0%)19/163 (11.7%)
Amlodipine 2.5 mg—1/161 (0.6%)12/161 (7.5%)
Valsartan + Amlodipine 40/2.5 mg—0/159 (0%)17/159 (10.7%)
Valsartan + Amlodipine 80/2.5 mg—1/160 (0.6%)9/160 (5.6%)
Amlodipine 5 mg—0/161 (0%)12/161 (7.5%)
Valsartan + Amlodipine 40/5 mg—1/167 (0.6%)20/167 (12%)
Valsartan + Amlodipine 80/5 mg—0/162 (0%)14/162 (8.6%)
Most frequent serious events
Most frequent serious events
EventPlaceboValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgValsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 80/2.5 mgAmlodipine 5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/5 mg
Compression fractureInjury, poisoning and procedural complications0/1660/1690/1630/1610/1591/1600/1610/1670/162
Supraventricular tachycardiaCardiac disorders0/1660/1690/1631/1610/1590/1600/1610/1670/162
Ulcerative keratitisEye disorders1/1660/1690/1630/1610/1590/1600/1610/1670/162
Pyelonephritis acuteInfections and infestations1/1660/1690/1630/1610/1590/1600/1610/1670/162
GastroenteritisInfections and infestations0/1660/1690/1630/1610/1590/1600/1611/1670/162
Most frequent other events
Most frequent other events
EventPlaceboValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgValsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 80/2.5 mgAmlodipine 5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/5 mg
NasopharyngitisInfections and infestations17/16623/16919/16312/16117/1599/16012/16120/16714/162

Baseline characteristics

Age Continuous
Age Continuous(years)Valsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/2.5 mgValsartan + Amlodipine 80/5 mgValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgAmlodipine 5 mgPlaceboTotal
Mean53.9 ± 10.3452.8 ± 10.7052.8 ± 10.7654.1 ± 9.7552.9 ± 10.0852.6 ± 11.2953.2 ± 10.8354.4 ± 10.6751.5 ± 10.5853.1 ± 10.57
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan + Amlodipine 40/2.5 mgValsartan + Amlodipine 40/5 mgValsartan + Amlodipine 80/2.5 mgValsartan + Amlodipine 80/5 mgValsartan 40 mgValsartan 80 mgAmlodipine 2.5 mgAmlodipine 5 mgPlaceboTotal
Female464940393849494055405
Male1131181201231311141121211111063
08

Study locations

1 site
  • Novartis Pharmaceuticals
    Tokyo, 11111, Japan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of Mar 2008 and a completion of Mar 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2011, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2007
First posted
Jan 23, 2007
Start
Nov 2006
Primary completionActual
Mar 2008
CompletionActual
Mar 2008
Results first posted
Feb 4, 2011
Last update
Apr 29, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00425373
First posted
Jan 23, 2007
Start date
Nov 2006
Primary completion
Mar 2008
Completion
Mar 2008
Results posted
Feb 4, 2011
Last update
Apr 29, 2011

Study contacts

Novartis Japan
study chair · Sponsor GmbH
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Amlodipine

Start the discussion